Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Goldhirsch A. Neoadjuvant chemotherapy for breast cancer: any progress? Lancet Oncol. 2014;15(2):131–132.
   PubMed Web of Science ®Google Scholar
• Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(11):1821–1828.
   PubMed Web of Science ®Google Scholar
• Benson JR. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer. J Clin Oncol. 2005;23(27):6807–6809.
   PubMed Web of Science ®Google Scholar
• Johnston SR, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14(10):989–998.
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–5116.
   PubMed Web of Science ®Google Scholar
• Fontein DB, Charehbili A, Nortier JW, et al. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients – a phase II trial. Eur J Cancer. 2014;50(13):2190–2200.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj. 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45(Pt A):139–145.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28(2):105–114.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Sugiu K, Iwamoto T, Kelly CM, et al. Neoadjuvant chemotherapy with or without concurrent hormone therapy in estrogen receptor-positive breast cancer: NACED-randomized multicenter phase II trial. Acta Med Okayama. 2015;69(5):291–299.
   PubMed Web of Science ®Google Scholar
• Yuyama Y, Yagihashi A, Hirata K, et al. Neoadjuvant intra-arterial infusion chemotherapy combined with hormonal therapy for locally advanced breast cancer. Oncol Rep. 2000;7(4):797–801.
   PubMed Web of Science ®Google Scholar
• Thomas JS, Julian HS, Green RV, et al. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. Histopathology. 2007;51(2):219–226.
   PubMed Web of Science ®Google Scholar
• Marcus DM, Switchenko JM, Prabhu R, et al. Neoadjuvant hormonal therapy is associated with comparable outcomes to neoadjuvant chemotherapy in post-menopausal women with estrogen receptor-positive breast cancer. Front Oncol. 2013;3:317.
   PubMedGoogle Scholar
• Gazet JC, Ford HT, Coombes RC. Randomised trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study). Br J Cancer. 1991;63(2):279–282.
   PubMed Web of Science ®Google Scholar
• Gazet JC, Ford HT, Gray R, et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol. 2001;12(5):685–691.
   PubMed Web of Science ®Google Scholar
• Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110(2):244–254.
   PubMed Web of Science ®Google Scholar
• Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23(12):3069–3074.
   PubMed Web of Science ®Google Scholar
• Palmieri C, Cleator S, Kilburn LS, et al. NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. Breast Cancer Res Treat. 2014;148(3):581–590.
   PubMed Web of Science ®Google Scholar
• Viale G, Regan MM, Maiorano E, et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors – International Breast Cancer Study Group. J Clin Oncol. 2008;26(9):1404–1410.
   PubMed Web of Science ®Google Scholar
• Pagani O, Gelber S, Simoncini E, et al. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group trials VII and 12-93. Breast Cancer Res Treat. 2009;116(3):491–500.
   PubMed Web of Science ®Google Scholar
• Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 1658-1667;295(14):2006.
   Google Scholar
• Leal F, Liutti VT, Antunes Dos Santos VC, et al. Neoadjuvant endocrine therapy for resectable breast cancer: a systematic review and meta-analysis. Breast. 2015;24(4):406–412.
   PubMed Web of Science ®Google Scholar
• Charehbili A, Fontein DB, Kroep JR, et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review. Cancer Treat Rev. 2014;40(1):86–92.
   PubMed Web of Science ®Google Scholar
• Generali D, Buffa FM, Berruti A, et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol. 2009;27(2):227–234.
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A, Guerrero A, Galan A, et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol. 2012;14(2):125–131.
   PubMed Web of Science ®Google Scholar
• Dixon JM, Renshaw L, Dixon J, et al. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Res Treat. 2011;130(3):871–877.
   PubMed Web of Science ®Google Scholar
• Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630–2637.
   PubMed Web of Science ®Google Scholar
• Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–2103.
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–2349.
   PubMed Web of Science ®Google Scholar